Alseres Pharma Wins FDA Approval to Lift Dose Level in Cethrin Phase I/IIa Clinical Trial

Alseres Pharmaceuticals, Inc. on Wednesday said that the U.S. Food and Drug Administration authorized an increase in the dose level of Cethrin to 9 mg in the company’s ongoing Phase I/IIa clinical study for the treatment of acute spinal cord injury.
RTTNews